.2 ppm. One quaternary carbon obscured by solvent. C NMR (CD 3 OD) δ 38. 2, 43.1, 46.6, 52.7, 102.6, 104.2, 122.2, 127.8, 129.4, 130.9, 134.2, 136.2, 136.2, 151.7, 152.4, 158 .2 ppm. C NMR (CD 3 OD) δ 38. 1, 43.2, 48.5, 51.5, 102.6, 104.2, 121.8, 122.0 (q, J = 256 Hz), 122.2, 133.4, 137.4, 149.4, 151.7, 152.4, 158 .3 ppm. 49.3, 51.4, 102.6, 104.2, 119.0, 122.0 (q, J = 255 Hz), 122.2, 124.4, 130.7, 130.7, 140.9, 150.4, 151.7, 152.4, 158 .3 ppm. 127.8, 129.6, 130.8, 134.8, 149.7, 151.7, 152.4, 158 .3 ppm. 3, 43.2, 49.4, 51.3, 55.6, 102.7, 104.2, 113.0, 117.7, 122.2, 124.1, 130.2, 139.6, 151.7, 152.4, 158.3, 161.1 ppm. 52.6, 55.7, 60.2, 102.6, 104.2, 112.0, 121.4, 122.2, 126.2, 129.4, 133.7, 151.7, 152.4, 158.3, 159 .5 ppm. 6, 52.8, 102.6, 104.2, 122.2, 129.3, 132.1, 133.4, 133.8, 134.7, 138.3, 151.7, 152.4, 158.2 ppm. 43.0, 52.9, 102.6, 104.2, 122.2, 128.2, 130.2, 132.5, 134.3, 134.4, 138.9, 151.7, 152.4, 158 .2 ppm. 131.6, 131.7, 133.0, 133.7, 139.1, 151.7, 152.4, 158.3 ppm. Piperidine C-2 carbon signal obscured by solvent. 126.5, 126.9, 128.6, 129.8, 130.4, 134.5, 134.7, 135.6 151.6, 152.4 3, 43.3, 49.4, 51.7, 102.6, 104.2, 122.2, 126.6, 127.1, 128.6, 128.7, 128.7, 130.2, 130.3, 133.8, 134.9, 135.7, 151.7, 152.4, 158 .3 ppm. S8 39.5, 54.1, 73.0, 74.3, 79.7, 79.8, 128.9, 129.1, 133.7, 137.2, 155 7, 43.0, 52.7, 73.6, 77.6, 102.5, 104.3, 122.4, 129.5, 130.4, 134.5, 138.4, 151.7, 152.4, 158.3 3, 27.4, 31.9, 37.9, 52.5, 63.5, 78.8, 79.6, 127.5, 127.7, 131.7, 136.6, 153.6, 155.2, 165.4 4, 37.0, 43.2, 53.4, 57.6, 102.2, 103.8, 121.8, 129.3, 129.6, 133.6, 137.3, 151.2, 152.0, 157.8, 176 .6 ppm. 8, 37.4, 43.7, 44.8, 58.0, 102.6, 104.3, 122.3, 127.2, 127.4, 127.7, 129.7, 134.7, 135.9, 151.7, 152.4, 158.2, 175 .9 ppm. 2, 34.6, 35.7, 41.6, 41.8, 48.3, 56.3, 61.8, 100.9, 102.1, 121.0, 125.2, 126.0, 128.0, 144.8, 150.6, 151.9, 156.2, 173 .4 ppm. 6, 44.7, 49.8, 64.9, 99.7, 101.3, 109.5, 121.8, 127.6, 130.8, 132.4, 136.6, 143.8, 149.9, 150 .8 ppm. 2, 34.1, 36.7, 44.8, 49.2, 49.8, 99.7, 101.3, 109.6, 121.8, 124.5, 130.3, 134.4, 143.8, 148.2, 150 6, 41.3, 45.8, 51.3, 105.4, 126.6, 128.5, 131.5, 134.4, 134.5, 135.0, 146.6, 149.5, 150.1, 153 .4 ppm. 2, 34.0, 36.7, 49.3, 49.8, 105.4, 124.4, 130.3, 134.3, 146.6, 148.1, 149.5, 150.1, 153 .4 ppm. 41.5, 55.4, 105.6, 128.1, 128.8, 131.1, 138.9, 146.5, 150.1, 153.4, 177 .1 ppm. 7, 45.6, 51.1, 100.9, 106.7, 129.3, 133.4, 133.7, 134.6, 136.9, 150.5, 153.1, 154.9 ppm. 8, 35.3, 37.7, 45.7, 47.9 (br), 51.1, 100.9, 106.7, 126.2, 131.6, 134.6, 134.9, 150.4, 150.7, 153 .1, 154.9.
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4-(3-(Trifluoromethoxy)benzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-piperidin-4-amine (6): LC-MS (10 min
)
4-(2-(Trifluoromethoxy)benzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-piperidin-4-amine (7): LC-MS (10 min
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4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(4-(trifluoromethoxy
4-Amino-N-(4-tert-butylbenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (27): LC-MS (10 min) m/z
4-Amino-N-(3,4-dichlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (29): LC-MS (10 min) m/z
4-Amino-N-(2,4-difluorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (30): LC-MS (10 min) m/z
4-Amino
General method for preparation of pyrrolo
General
4-
4-(4-
General method for preparation
2.
Kinase panel selectivity data for compounds 2, 10 and 21 Following this, cells were fixed with 3% paraformaldehyde, 0.25% glutaraldehyde, 0.25% Triton-X100 and blocked with 5% milk in TBST prior to overnight incubation with a phospho-GSK3β (serine 9) antibody (Cell Signaling Technology). The plates were then washed, secondary antibody added, and enhancement of the signal performed using DELFIA reagents (Perkin Elmer) as stated in the manufacturer's instructions. Europium counts were normalized to the protein concentration, and the IC 50 value for each inhibitor was calculated in GraphPad Prism 4.00 using non-linear regression analysis and a sigmoidal dose response (variable slope) equation.
S23
5.
Details of the X-ray crystallography data collection and refinement for 10-PKB and 21-PKB X-ray structure determinations for the PKBβ inhibitor complexes discussed in this paper were carried out as described previously
26
.
Data collection and refinement statistics are presented in Table S2 . Coordinates and structure factors for the complexes have been deposited with the PDB with the following accession codes: 2x37 (10-PKB) and 2x37 (21-PKB). 
